Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Guggenheim revised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $284 from $224 and reiterated a Buy rating on the shares following the company’s fiscal Q4 report. Krystal Biotech, Inc. (NASDAQ:KRYS) announced its fiscal Q4 and full year 2025 financial results on February 17, reporting that it recorded $107.1 million and $389.1 million in VYJUVEK net product revenue for fiscal Q4 and full year 2025, respectively.

The company further reported that it has secured over 660 reimbursement approvals for VYJUVEK in the United States and is continuing to maintain strong access nationwide. Steady VYJUVEK uptake is being driven by high patient demand since launch in Germany, France, and Japan, and Krystal Biotech’s (NASDAQ:KRYS) estimates show that over 90 patients have been prescribed VYJUVEK therapy across the three countries. It is advancing pricing discussions with the reimbursement authorities in Italy and is currently on track for a potential launch in the second half of 2026. Krystal Biotech, Inc. (NASDAQ:KRYS) also reported a strong balance sheet, ending the quarter with $955.9 million in cash and investments.

Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company that develops and commercializes pharmaceutical products and offers the product VYJUVEK, which is a topical gel that treats wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB).

While we acknowledge the potential of KRYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.